Informative combination of CLU rs11136000, serum HDL levels, diabetes, and age as a new piece of puzzle-picture of predictive medicine for cognitive disorders

  • Mohsen Aghajanpour-Mir
  • Fatemeh Amjadi-Moheb
  • Tahereh Dadkhah
  • Seyed Reza Hosseini
  • Elham Ghadami
  • Ehsan Assadollahi
  • Haleh Akhavan-Niaki
  • Alijan Ahmadi Ahangar
Original Article


Clusterin (CLU) is the third most important associated risk gene in cognitive disorders. Regarding the controversy about the association of CLU rs11136000 with mild cognitive impairment (MCI), the aim of this study was to investigate a putative association of CLU rs11136000 with MCI as well as the serum biological factors with a special attention to the age as a main dimension of a multifactorial elderly disease in an Iranian elderly cohort in which the mentioned association was not previously investigated. The study also checked the association between diabetes and MCI in this population. A population of 418 individuals containing 236 MCI and 192 control subjects was recruited from the Amirkola health and aging population cohort. Serum biological indexes were assessed by biochemical and enzyme-linked immunosorbent assay, and rs11136000 genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism. Bioinformatics analyses were used to identify the putative effect of rs11136000 on the secondary structure of RNA and chromatin location in different cell lines and tissues. Type 2 diabetes was present with a higher proportion in the MCI group in comparison with the control group (P = 0.041). The frequency of the C allele of CLU rs11136000 was significantly different between cases and controls and was associated with MCI risk (OR 1.79, P = 0.019). Under a dominant genetic model, the CC genotype showed a predisposing effect in individuals aged ≥ 75 years (OR 3.33, P = 0.0004). Interestingly, under an over-dominant model, the CT genotype had a protective effect in this population (OR 4.52, P = < 0.0001). We also found a significant association between the genotypes and high-density lipoprotein (HDL) levels in MCI patients (P = 0.0004). Bioinformatics analysis showed that rs11136000 is located in the transcribed region without any regulatory features such as being enhancer or insulator. Also, the T>C transition of CLU rs11136000 could not cause significant mRNA folding (P = 0.950). Contrary to other studies on Asian populations, this study demonstrated an association between rs11136000 and MCI in an elderly Iranian population. This study also suggests that an age-dependent approach to the previous studies may be performed in order to revise the previous belief in this geographical area. The rs11136000 genotypes in combination with HDL levels and knowledge about diabetes background may be used as a predictive medicine tool for cognitive disorders.


Clusterin Rs11136000 Mild cognitive impairment HDL Age Predictive medicine 



The authors would like to acknowledge all participants of this study. The present study was supported by a Grant No. 9339436 of Babol University of Medical Sciences, Babol, Iran.

Compliance with ethical standards

Conflict of interest

Authors declare no conflict of interest.


  1. 1.
    Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12(1):23–35PubMedCrossRefGoogle Scholar
  2. 2.
    Jaul E, Barron J (2017) Age-related diseases and clinical and public health implications for the 85 years old and over population. Front Public Health 5:335PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Chentli F, Azzoug S, Mahgoun S (2015) Diabetes mellitus in elderly. Indian J Endocrinol Metab 19(6):744–752PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Cukierman T, Gerstein H, Williamson J (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48(12):2460–2469PubMedCrossRefGoogle Scholar
  5. 5.
    Cheng G et al (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42(5):484–491PubMedCrossRefGoogle Scholar
  6. 6.
    de Silva HV et al (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29(22):5380–5389PubMedCrossRefGoogle Scholar
  7. 7.
    Thambisetty M et al (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59(1):212–217PubMedCrossRefGoogle Scholar
  8. 8.
    Thambisetty M et al (2013) Alzheimer risk variant CLU and brain function during aging. Biol Psychiatr 73(5):399–405CrossRefGoogle Scholar
  9. 9.
    Thambisetty M et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatr 67(7):739–748PubMedCrossRefGoogle Scholar
  10. 10.
    Park S, Mathis K, Lee I (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53PubMedCrossRefGoogle Scholar
  11. 11.
    Haase CL et al (2015) HDL cholesterol and risk of type 2 diabetes: a mendelian randomization study. Diabetes 64(9):3328–3333PubMedCrossRefGoogle Scholar
  12. 12.
    Park S, Mathis KW, Lee IK (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53PubMedCrossRefGoogle Scholar
  13. 13.
    Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Human Mol Genet 18(R2):R137–R145CrossRefGoogle Scholar
  14. 14.
    Carrasquillo MM et al (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 67(8):961–964PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Corneveaux JJ et al (2010) Association of CR1, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Mol Genet 19(16):3295–3301CrossRefGoogle Scholar
  16. 16.
    Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lancaster TM et al (2015) Alzheimer’s disease risk variant in CLU is associated with neural inefficiency in healthy individuals. Alzheimer’s Dement 11(10):1144–1152CrossRefGoogle Scholar
  18. 18.
    Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17PubMedCrossRefGoogle Scholar
  19. 19.
    Gu H et al (2011) Association of clusterin gene polymorphisms with late-onset Alzheimer’s disease. Dementia Geriatr Cognit Disord 32(3):198–201CrossRefGoogle Scholar
  20. 20.
    Han Z et al (2018) Analyzing 74,248 samples confirms the association between clu rs11136000 polymorphism and Alzheimer’s disease in caucasian but not Chinese population. Sci Rep 8(1):11062PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Jen MY, Gossman WG (2018) Predictive medicine. StatPearls, OrlandoGoogle Scholar
  22. 22.
    Hosseini SR et al (2014) Cohort profile: the Amirkola health and ageing project (AHAP). Int J Epidemiol 43(5):1393–1400PubMedCrossRefGoogle Scholar
  23. 23.
    Ansari NN et al (2010) Validation of a mini-mental state examination (MMSE) for the Persian population: a pilot study. Appl Neuropsychol 17(3):190–195PubMedCrossRefGoogle Scholar
  24. 24.
    Ernst J, Kellis M (2012) ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 9(3):215–216PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Gonzalez JR et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5):644–645PubMedCrossRefGoogle Scholar
  26. 26.
    Allen M et al (2012) Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 79(3):221–228PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Rizzuto D et al (2012) Dementia after age 75: survival in different severity stages and years of life lost. Curr Alzheimer Res 9(7):795–800PubMedCrossRefGoogle Scholar
  28. 28.
    Grundman M et al (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61(1):59–66PubMedCrossRefGoogle Scholar
  29. 29.
    Daimon M et al (2011) Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism 60(6):815–822PubMedCrossRefGoogle Scholar
  30. 30.
    Han BH et al (2001) Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med 7(3):338–343PubMedCrossRefGoogle Scholar
  31. 31.
    Leskov KS et al (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278(13):11590–11600PubMedCrossRefGoogle Scholar
  32. 32.
    Saedi E et al (2016) Diabetes mellitus and cognitive impairments. World J Diabetes 7(17):412–422PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Kodl CT, Seaquist ER (2008) Cognitive dysfunction and diabetes mellitus. Endocr Rev 29(4):494–511PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Munshi MN (2017) Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 40(4):461–467PubMedCrossRefGoogle Scholar
  35. 35.
    Abbatecola AM et al (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67(2):235–240PubMedCrossRefGoogle Scholar
  36. 36.
    Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet 18(R2):R137–R145PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Cai R et al (2016) Plasma clusterin and the CLU gene rs11136000 variant are associated with mild cognitive impairment in type 2 diabetic patients. Front Aging Neurosci 8:179PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Tan L et al (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. Sci Rep 6:26027PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Morgantini C et al (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60(10):2617–2623PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Gordon SM et al (2011) High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab 22(1):9–15PubMedCrossRefGoogle Scholar
  41. 41.
    Drew BG et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119(15):2103–2111PubMedCrossRefGoogle Scholar
  42. 42.
    Brunham LR et al (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13(3):340–347PubMedCrossRefGoogle Scholar
  43. 43.
    Han R et al (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50(9):1960–1968PubMedCrossRefGoogle Scholar
  44. 44.
    Rojano E et al (2018) Regulatory variants: from detection to predicting impact. Brief Bioinform. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Genetics, Faculty of MedicineBabol University of Medical SciencesBabolIran
  2. 2.Department of Medical Genetics, School of MedicineTehran University of Medical SciencesTehranIran
  3. 3.Social Determinants of Health (SDH) Research Center, Health Research InstituteBabol University of Medical SciencesBabolIran
  4. 4.Student Research CommitteeBabol University of Medical SciencesBabolIran
  5. 5.Mobility Impairment Research CenterBabol University of Medical Sciences, University of Medical SciencesBabolIran

Personalised recommendations